WO2022180393A3 - Treatment of ovarian cancer minimal residual disease - Google Patents

Treatment of ovarian cancer minimal residual disease Download PDF

Info

Publication number
WO2022180393A3
WO2022180393A3 PCT/GB2022/050497 GB2022050497W WO2022180393A3 WO 2022180393 A3 WO2022180393 A3 WO 2022180393A3 GB 2022050497 W GB2022050497 W GB 2022050497W WO 2022180393 A3 WO2022180393 A3 WO 2022180393A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian cancer
residual disease
minimal residual
treatment
relates
Prior art date
Application number
PCT/GB2022/050497
Other languages
French (fr)
Other versions
WO2022180393A2 (en
Inventor
Ahmed Ahmed
Mara ARTIBANI
Original Assignee
Oxford University Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Limited filed Critical Oxford University Innovation Limited
Priority to GB2314598.0A priority Critical patent/GB2619478A/en
Publication of WO2022180393A2 publication Critical patent/WO2022180393A2/en
Publication of WO2022180393A3 publication Critical patent/WO2022180393A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Abstract

The present invention relates to a method of preventing or treating ovarian cancer minimal residual disease (MRD) in a subject. The invention relates to administering an effective amount of an agent which reduces intracellular lipid metabolism, particularly an agent which reduces fatty acid metabolism. The invention also relates to a method of obtaining an indication of the risk to a subject of having or developing a MRD.
PCT/GB2022/050497 2021-02-24 2022-02-23 Treatment of ovarian cancer minimal residual disease WO2022180393A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2314598.0A GB2619478A (en) 2021-02-24 2022-02-23 Treatment of ovarian cancer minimal residual disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2102606.7A GB202102606D0 (en) 2021-02-24 2021-02-24 Treatment of ovarian cancer minimal residual disease
GB2102606.7 2021-02-24

Publications (2)

Publication Number Publication Date
WO2022180393A2 WO2022180393A2 (en) 2022-09-01
WO2022180393A3 true WO2022180393A3 (en) 2022-10-13

Family

ID=75339170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2022/050497 WO2022180393A2 (en) 2021-02-24 2022-02-23 Treatment of ovarian cancer minimal residual disease

Country Status (2)

Country Link
GB (2) GB202102606D0 (en)
WO (1) WO2022180393A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024442A2 (en) * 2001-09-18 2003-03-27 G2M Cancer Drugs Ag Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors
WO2020065023A1 (en) * 2018-09-27 2020-04-02 Vaccibody As Method for selecting neoepitopes
WO2020174211A1 (en) * 2019-02-27 2020-09-03 Oxford University Innovation Limited High-grade serous ovarian carcinoma (hgsoc)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024442A2 (en) * 2001-09-18 2003-03-27 G2M Cancer Drugs Ag Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors
WO2020065023A1 (en) * 2018-09-27 2020-04-02 Vaccibody As Method for selecting neoepitopes
WO2020174211A1 (en) * 2019-02-27 2020-09-03 Oxford University Innovation Limited High-grade serous ovarian carcinoma (hgsoc)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREA GARCIA-GARIJO ET AL: "Determinants for Neoantigen Identification", FRONTIERS IN IMMUNOLOGY, vol. 10, no. 1392, 24 June 2019 (2019-06-24), pages 1 - 19, XP055630095, DOI: 10.3389/fimmu.2019.01.01392 *

Also Published As

Publication number Publication date
GB202102606D0 (en) 2021-04-07
WO2022180393A2 (en) 2022-09-01
GB202314598D0 (en) 2023-11-08
GB2619478A (en) 2023-12-06

Similar Documents

Publication Publication Date Title
Crouch et al. Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation
Nuber et al. A Stearoyl–Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in α‐Synuclein Mice
CY1111359T1 (en) Memantine for the treatment of mild to moderate ALZHEIMER
NO20063328L (en) Use of a fatty acid composition comprising at least one of EPA and DHA or combinations thereof
CO6351728A2 (en) METHODS TO TREAT TALASEMIA
WO2006055526A3 (en) Compositions useful to treat ocular neovascular diseases and macular degeneration
CO2021009163A2 (en) Amyloid precursor protein (app) arni agent compositions and method of use thereof
EP3301090B1 (en) Derivatives of 2-amino-2-(1-dodecyl-1h-1,2,3-triazol-4-yl)propane-1,3-diol useful in the treatment of neurodegenerative diseases or depressions
WO2005013947A3 (en) Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
ZA202106809B (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
BR112022007595A2 (en) METHODS TO TREAT ALZHEIMER'S DISEASE
Liu et al. Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure
WO2022180393A3 (en) Treatment of ovarian cancer minimal residual disease
MX2022001084A (en) Method for treating alzheimer's disease by regulating intestinal microorganisms.
JP2005082523A5 (en)
FR3079141B1 (en) USES OF CURCUMIN DERIVATIVES
Kaur et al. Hyperhomocysteinemia: an overview
WO2001068075A3 (en) Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
PH12020551470A1 (en) Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
MX2022005596A (en) Dosing regimen for anti-dll3 agents.
Miyahara et al. Negative feedback loop of cholesterol regulation is impaired in the livers of patients with Alagille syndrome
MX2022012252A (en) Methods for treating alzheimer's disease.
Campbell Vitamin K^ sub 2^ in the Prevention of Cardiovascular Diseases and Diabetes
Cicero et al. A case of severe leg oedema in a patient with Parkinson's disease treated with pramipexole
Van Kester et al. A female with hereditary angioedema developing wheals: a case report

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22707494

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 202314598

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20220223

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22707494

Country of ref document: EP

Kind code of ref document: A2